Chimerix (CMRX)
(Delayed Data from NSDQ)
$0.94 USD
0.00 (-0.27%)
Updated May 28, 2024 04:00 PM ET
After-Market: $0.94 0.00 (0.48%) 7:58 PM ET
4-Sell of 5 4
C Value F Growth B Momentum D VGM
Brokerage Reports
0 items in cart
Chimerix, Inc. [CMRX]
Reports for Purchase
Showing records 61 - 80 ( 115 total )
Company: Chimerix, Inc.
Industry: Medical - Products
Company: Chimerix, Inc.
Industry: Medical - Products
Company: Chimerix, Inc.
Industry: Medical - Products
Deep Dive Into ONC201 in Recurrent H3 K27M-mutant DMG Data at Society for Neuro-Oncology Annual Meeting; Raising PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Chimerix, Inc.
Industry: Medical - Products
Company: Chimerix, Inc.
Industry: Medical - Products
Company: Chimerix, Inc.
Industry: Medical - Products
Company: Chimerix, Inc.
Industry: Medical - Products
Company: Chimerix, Inc.
Industry: Medical - Products
Positive Data Announced For ONC201 in Recurrent H3 K27M-mutant Diffuse Midline Glioma
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Chimerix, Inc.
Industry: Medical - Products
3Q21 Results; Positive ONC201 Data Readout; RFP for Smallpox Strategic National Stockpile Contract Expected Soon
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Chimerix, Inc.
Industry: Medical - Products
Company: Chimerix, Inc.
Industry: Medical - Products
Company: Chimerix, Inc.
Industry: Medical - Products
Company: Chimerix, Inc.
Industry: Medical - Products
2Q21 Results; DSTAT in AML Efficacy Analysis in 2H22; Potential Small Pox RFP Approaching
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Chimerix, Inc.
Industry: Medical - Products
Company: Chimerix, Inc.
Industry: Medical - Products
Smallpox Beware: TEMBEXA Receives FDA Approval
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Chimerix, Inc.
Industry: Medical - Products
Tembexa Approved For Smallpox; Raising Price Target to $19
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Chimerix, Inc.
Industry: Medical - Products
ASCO 2021 Abstract Roundup for Covered Companies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Chimerix, Inc.
Industry: Medical - Products
Continued DSTAT Focus on AML as COVID-19 Trial Stopped; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Chimerix, Inc.
Industry: Medical - Products
Company: Chimerix, Inc.
Industry: Medical - Products
1Q21 Results; Brincidofovir PDUFA July 7; Raising PT by $2
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E